Literature DB >> 8806195

Tumor angiogenesis: the pivotal role of vascular endothelial growth factor.

D Marmé1.   

Abstract

There is considerable evidence that vascular endothelial growth factor is involved in the vascularization and growth of primary tumors and in the formation of metastases. The expression of vascular endothelial growth factor depends on activated oncogenes and inactivated tumor-suppressor genes as well as several other factors, e.g., growth factors, hypoxia, and tumor promoters. Substantial expression of vascular endothelial growth factor receptors is mainly restricted to tumor vessels. The causal involvement of this angiogenic factor in the progression of the disease has been successfully evaluated using monoclonal antibodies against vascular endothelial growth factor, dominant negative receptor mutants, and antisense oligonucleotides against the messenger RNA of vascular endothelial growth factor. Thus, the vascular endothelial growth factor-signaling system seems to be an appropriate target for inhibition of tumor angiogenesis and metastasis formation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806195     DOI: 10.1007/bf00186896

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  88 in total

Review 1.  Inhibitors of angiogenesis.

Authors:  M A Moses; R Langer
Journal:  Biotechnology (N Y)       Date:  1991-07

2.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

3.  Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.

Authors:  J Kandel; E Bossy-Wetzel; F Radvanyi; M Klagsbrun; J Folkman; D Hanahan
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

4.  Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.

Authors:  S Kondo; M Asano; H Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1993-08-16       Impact factor: 3.575

5.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

Authors:  D R Senger; C A Perruzzi; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

7.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Authors:  K T Yeo; H H Wang; J A Nagy; T M Sioussat; S R Ledbetter; A J Hoogewerf; Y Zhou; E M Masse; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701

8.  Quantitative RT-PCR assay detecting the transcriptional induction of vascular endothelial growth factor under hypoxia.

Authors:  M Iizuka; M Yamauchi; K Ando; N Hori; Y Furusawa; H Itsukaichi; K Fukutsu; H Moriya
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

9.  Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors.

Authors:  F Czubayko; R V Smith; H C Chung; A Wellstein
Journal:  J Biol Chem       Date:  1994-11-11       Impact factor: 5.157

10.  Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis.

Authors:  J Strugar; D Rothbart; W Harrington; G R Criscuolo
Journal:  J Neurosurg       Date:  1994-10       Impact factor: 5.115

View more
  8 in total

1.  Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.

Authors:  Bohan Yang; Dandan Yu; Jingwen Liu; Kunyu Yang; Gang Wu; Hongli Liu
Journal:  Tumour Biol       Date:  2015-02-04

2.  Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma.

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Shou-Chuan Shih; Chih-Roa Kao; Wen-Hsing Chang; Horng-Yuan Wang; Po-Chuan Wang; Tsang-En Wang; Li-Rung Shyung; Chih-Zen Chen
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

3.  Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.

Authors:  R T Poon; I O Ng; C Lau; L X Zhu; W C Yu; C M Lo; S T Fan; J Wong
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

4.  Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?

Authors:  Kuo-Shyang Jeng; I-Shyan Sheen; Yi-Ching Wang; Shu-Ling Gu; Chien-Ming Chu; Shou-Chuan Shih; Po-Chuan Wang; Wen-Hsing Chang; Horng-Yuan Wang
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

5.  Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy.

Authors:  Rashmi K Ambasta; Archita Sharma; Pravir Kumar
Journal:  Vasc Cell       Date:  2011-11-14

6.  The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease.

Authors:  G P Pidgeon; J H Harmey; E Kay; M Da Costa; H P Redmond; D J Bouchier-Hayes
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

Review 7.  Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia.

Authors:  Hee Seung Kim; Taehun Kim; Mi-Kyung Kim; Dong Hoon Suh; Hyun Hoon Chung; Yong Sang Song
Journal:  J Cancer Prev       Date:  2013-06

Review 8.  Fucoidan as a Potential Therapeutic for Major Blinding Diseases--A Hypothesis.

Authors:  Alexa Klettner
Journal:  Mar Drugs       Date:  2016-02-03       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.